Greenwich LifeSciences (GLSI) to Release Quarterly Earnings on Wednesday

Key Points

• Greenwich LifeSciences (GLSI) is expected to report its quarterly earnings on August 13th, with analysts forecasting a loss of ($0.24) per share.
• In its last earnings report, Greenwich missed expectations by reporting ($0.25) EPS, and analysts predict a total of ($1 EPS) for both the current and next fiscal years.
• Institutional investors have been active, with notable increases in holdings, including a 48.7% increase by Rhumbline Advisers in the first quarter.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) is projected to release its earnings data before the market opens on Wednesday, August 13th. Analysts expect Greenwich LifeSciences to post earnings of ($0.24) per share for the quarter.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last released its quarterly earnings results on Tuesday, May 20th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.01). On average, analysts expect Greenwich LifeSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Greenwich LifeSciences Trading Up 3.8%

NASDAQ:GLSI traded up $0.45 during trading hours on Friday, reaching $12.12. 10,253 shares of the company were exchanged, compared to its average volume of 58,176. The firm has a market cap of $161.98 million, a PE ratio of -9.62 and a beta of 1.65. Greenwich LifeSciences has a twelve month low of $8.06 and a twelve month high of $16.50. The stock's 50-day moving average is $10.24 and its 200-day moving average is $10.65.

Wall Street Analyst Weigh In

Separately, HC Wainwright raised their price target on shares of Greenwich LifeSciences from $38.00 to $39.00 and gave the company a "buy" rating in a research note on Monday, April 21st.

Institutional Trading of Greenwich LifeSciences

Large investors have recently bought and sold shares of the business. Rhumbline Advisers grew its position in shares of Greenwich LifeSciences by 48.7% in the first quarter. Rhumbline Advisers now owns 9,673 shares of the company's stock valued at $92,000 after purchasing an additional 3,168 shares in the last quarter. Strs Ohio purchased a new stake in Greenwich LifeSciences in the 1st quarter valued at $177,000. Finally, Bank of America Corp DE raised its holdings in shares of Greenwich LifeSciences by 22.3% during the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock worth $82,000 after acquiring an additional 1,322 shares during the period. Hedge funds and other institutional investors own 4.16% of the company's stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.